Evidence map›Paper›PMID 34320789›Full record

ArticleHaematologica2022

Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.

Ohad Benjamini, Lior Rokach, Gilad Itchaki, Andrei Braester, Lev Shvidel, Neta Goldschmidt, Shirley Shapira, Najib Dally, Abraham Avigdor, Galia Rahav and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 11 pooled it
12.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 11 syntheses or guidelines pooled it, 100 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review.Annals of oncology : official journal of the European Society for Medical Oncology · 2022
    Pooled it
  9. Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022
    Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Article
  18. Article
  19. Article
  20. Review

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 11 institutions in 1 country.

Ohad BenjaminiHematology Division, Chaim Sheba Medical Center, Tel-Hashomer; Sackler Faculty of Medicine, Tel-Aviv University, Israel.
Lior RokachDepartment of Software and Information Systems Engineering, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Gilad ItchakiInstitute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel.
Andrei BraesterDepartment of Hematology Galilee Medical Center, Nahariya, Israel.
Lev ShvidelHematology Institute, Kaplan Medical Center, Rehovot, Israel.
Neta GoldschmidtHematology, Hadassah Medical Center, Jerusalem, Israel.
Shirley ShapiraHealth Division, Maccabi Healthcare Services, Aviv.
Najib DallyDivision of Hematology, Ziv Medical Center, Safed, Israel.
Abraham AvigdorHematology Division, Chaim Sheba Medical Center, Tel-Hashomer; Sackler Faculty of Medicine, Tel-Aviv University, Israel.
Galia RahavThe Infectious Disease Unit, Sheba Medical Center, Tel-Hashomer, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Israel.
Yaniv LustigCentral Virology Laboratory, Ministry of Health and Sheba Medical Center, Tel-Hashomer, Israel.
Shirley Shapiro Ben DavidHealth Division, Maccabi Healthcare Services, Aviv.
Riva FinemanDepartment of Hematology and BMT, Rambam Health Care Campus, Haifa, Israel.
Alona PazInfectious Disease Unit, Bnai Zion Medical Center, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.
Osnat BaireyInstitute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel.
Aaron PolliackHematology, Hadassah Medical Center, Jerusalem, Israel.
Ilana LevyHematology Unit, Bnai Zion Medical Center, Haifa, Israel.
Tamar TadmorThe Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel; Hematology Unit, Bnai Zion Medical Center, Haifa, Israel. Tamar.tadmor@b-zion.org.il.
Bnai Zion Medical Center · ILHadassah Medical Center · ILRabin Medical Center · ILSheba Medical Center · ILBen-Gurion University of the Negev · ILIsrael Ministry of Health · ILKaplan Medical Center · ILRambam Health Care Campus · ILRebecca Sieff Hospital · ILTel Aviv University · ILWestern Galilee Hospital · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with chronic lymphocytic leukemia (CLL) have a suboptimal humoral response to vaccination. Recently, BNT162b2, an mRNA COVID-19 vaccine with a high efficacy of 95% in immunocompetent individuals, was introduced. We investigated the safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with CLL from nine medical centers in Israel, Overall 400 patients were included, of whom 373 were found to be eligible for the analysis of antibody response. The vaccine appeared to be safe and only grade 1-2 adverse events were seen in 50% of the patients. Following the second dose, an antibody response was detected in 43% of the cohort. Among these CLL patients, 61% of the treatment-na ve patients responded to the vaccine, while responses developed in only 18% of those with ongoing disease, 37% of those previously treated with a BTK inhibitor and 5% of those recently given an anti-CD20 antibody. Among patients treated with BCL2 as monotherapy or in combination with anti-CD20, 62% and 14%, respectively, developed an immune response. There was a high concordance between neutralizing antibodies and positive serological response to spike protein. Based on our findings we developed a simple seven-factor score including timing of any treatment with anti-CD20, age, treatment status, and IgG, IgA, IgM and hemoglobin levels. The sum of all the above parameters can serve as a possible estimate to predict whether a given CLL patient will develop sufficient antibodies. In conclusion, the BNT162b2 mRNA COVID-19 vaccine was found to be safe in patients with CLL, but its efficacy is limited, particularly in treated patients.

Indexed as

COVID-19Leukemia, Lymphocytic, Chronic, B-CellAntibodies, ViralBNT162 VaccineCOVID-19 VaccinesHumansRNA, MessengerSARS-CoV-2Antibodies, ViralBNT162 VaccineCOVID-19 VaccinesRNA, Messenger

Identifiers

PMID34320789
PMCPMC8883569
OpenAlexW3183326508

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.